Activity Provided By:

The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

CAR-T Therapy: What’s in the CARds? – Module 1

Overview / Abstract:	Target Audience This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers. Program Overview This activity provides an overview of CAR T-cell development, available CAR T-cell products for blood cancers, and important side effects of CAR T-cell therapy. Learning Objective Upon completion of this activity, participants should be better able to: Describe the current state of chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies
Expiration	Mar 02, 2023
Discipline(s)	Physician CME
Format	Online
Credits / Hours	1.0 AMA PRA Category 1 Credit(s)™
Accreditation	ACCME
Presenters / Authors / Faculty	Faculty FACULTY_NAME Carl H. June, MD Richard W. Vague Professor, Immunotherapy Director, Center for Cellular Immunotherapies Director, Parker Institute for Cancer Immunotherapy University of Pennsylvania Perelman School of Medicine Philadelphia, PA
Sponsors / Supporters / Grant Providers	The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.
Keywords / Search Terms	Relias LLC Relias LLC., FreeCME., Leukemia & Lymphoma Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map